末梢神経障害

出版社： 中外医学社
著者：
発行日： 2018-02-01
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498228986
電子書籍版： 2018-02-01 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

7,260 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,260 円(税込)

購入する

商品紹介

神経内科のエキスパートをめざす医師に贈る新シリーズの末梢神経疾患編。診療のエッセンスをエビデンスも交えてコンパクトに凝縮し，Q&A形式で読みやすく解説しました．各Q&Aの最後にはエキスパートの診療のエッセンスを学べるコラム「pearls」を掲載．基礎から応用まで，末梢神経疾患の診療に関するあらゆる「困った！」に第一人者がお答えします。

目次

  • I　検査
    　1　脱髄と軸索変性はどのように見分けるのでしょうか？
    　2　‌遺伝性ニューロパチーと炎症性ニューロパチーは電気生理で鑑別できますか？
    　3　血液検査はどのくらい役に立ちますか？
    　4　脳脊髄液検査はどのくらい役に立ちますか？
    　5　‌末梢神経生検はどんな時に適応になりますか？どのくらい役に立ちますか？
    　6　超音波診断はどのくらい役に立ちますか？
    　7　MRIはどのくらい役に立ちますか？

    II　臨床診断と治療
    　1　一側動眼神経麻痺の鑑別診断は？
    　2　三叉神経障害の鑑別診断は？
    　3　三叉神経痛はどのように治療しますか？
    　4　末梢性顔面神経麻痺（一側，両側）の鑑別診断は？
    　5　Bell麻痺の治療はどのように行いますか？
    　6　‌一側上肢の運動感覚障害の患者，頸椎症と末梢神経障害の鑑別ポイントは？
    　7　‌一側下肢の運動感覚障害の患者，腰部神経根障害と末梢神経障害の鑑別のポイントは？
    　8　多発性単ニューロパチーの鑑別診断は？
    　9　純粋感覚性多発ニューロパチーの鑑別診断は？
    　10　‌手根管症候群はどのようにして診断しますか？内科的治療は？
    　11　‌手根管症候群で手術療法を選択するのはどのような場合ですか？
    　12　‌胸郭出口症候群はどのように診断しますか？治療は？
    　13　痛みの治療はどのように進めればよいでしょうか？
    　14　しびれ感，異常感覚の治療はどのように行いますか？
    　15　自律神経ニューロパチーはどのように治療しますか？
    　16　‌末梢神経障害にリハビリテーションはどの程度有効でしょうか？

    III　遺伝性末梢神経障害
    　1　遺伝性末梢神経障害を疑うポイントは何でしょうか？
    　2　‌遺伝子を調べれば遺伝性末梢神経障害は診断できますか？
    　3　‌Charcot—Marie—Tooth病での整形外科的治療にはどのようなものがありますか？
    　4　FAPはどんな患者で疑わないといけませんか？
    　5　FAPはどのように治療しますか？
    　6　‌Fabry病はどんな患者で疑わないといけませんか？どのように治療しますか？
    　7　‌末梢神経障害を合併する変性疾患にはどのようなものがありますか？
    case approach　FAP

    IV　代謝性・中毒性末梢神経障害
    　1　‌ビタミン測定は末梢神経疾患の診断にどの程度役に立ちますか？
    　2　‌糖尿病性神経障害の末梢神経障害はどのように鑑別を進めますか？
    　3　糖尿病性ニューロパチーはどのように治療しますか？
    　4　‌ビタミンB1ニューロパチーはどのような患者で疑いますか？どのように治療しますか？
    　5　‌n—ヘキサン中毒による末梢神経障害はどのように診断しますか？
    　6　‌砒素中毒による末梢神経障害はどのように診断しますか？
    　7　‌末梢神経障害をきたす薬剤にはどのようなものがありますか？
    　　　どんな場合に薬剤性ニューロパチーを考えないといけませんか？
    　case approach　ビタミンB1欠乏性ニューロパチー

    V　自己免疫性末梢神経障害
    　1　‌炎症性末梢神経障害で末梢神経生検は診断の役に立ちますか？
    　2　GBSの診断はどのように進めればよいでしょうか？
    　3　GBSに似て非なる病気にはどのようなものがあるでしょうか？
    　4　GBSの脱髄型，軸索型の鑑別にはどのような意味がありますか？
    　5　GBSはどのように治療しますか？
    　6　CIDPの鑑別診断はどのように進めればよいでしょうか？
    　7　‌単クローン性ガンマグロブリンを有する末梢神経障害をどのように診断，治療しますか？
    　8　MMNとALSの鑑別ポイントは？
    　9　CIDPの治療はどのように進めていけばよいでしょうか？
    　10　MMN治療はどのように進めていけばよいでしょうか？
    　11　‌全身臓器障害が出る前にPOEMS症候群を診断するポイントは？
    　12　Fisher症候群は免疫治療する必要がありますか？
    　13　‌神経痛性筋萎縮症はどのように診断・治療しますか？
    　　　　発症後時間が経っていても治療する意味がありますか？
    　14　‌特発性前骨間神経麻痺，特発性後骨間神経麻痺とはどんな病気ですか？
    　　　　どのように治療しますか？
    　case approach　GBS

    VI　内科疾患に伴う末梢神経障害
    　1　‌末梢神経障害をきたす血管炎にはどのようなものがありますか？どのように診断しますか？
    　2　血管炎性末梢神経障害の治療はどのように進めますか？
    　3　‌サルコイドニューロパチーはどのような時に疑い，どのように診断し，治療しますか？
    　4　‌Sjögren症候群にみられる末梢神経障害にはどのようなものがありますか？
    　　　どのように治療しますか？
    　5　傍腫瘍性末梢神経障害はどんな時に疑いますか？
    　6　‌悪性リンパ腫に伴う末梢神経障害にはどのような特徴がありますか？
    　7　‌Hansen病に伴う末梢神経障害の特徴は？診断はどのように行いますか？
    　case approach　サルコイドニューロパチー

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 検査

P.13 掲載の参考文献
(1) Kurihara S, Adachi Y, Wada K, et al. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan. Neuroepidemiplogy. 2002;21:246-50.
 
(2) Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. 1982;32:592-6.
 
(3) 園生雅弘. 末梢神経疾患の電気診断:脱髄性ニューロパチーを中心に. 末梢神経. 2012;23:215-23.
 
(4) Lupu VD, Mora CA, Dambrosia J, et al. Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve. 2007;35:196-202.
 
(5) Attarian S, Azulay JP, Boucraut J, et al. Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies. Clin Neurophysiol. 2001;112:457-63.
 
(6) Michell AW, Laura M, Blake J, et al. GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment. J Neurol Neurosurg Psychiatry. 2009;80:699-700.
 
(7) Mazzeo A, Stancanelli C, Russo M, et al. Subacute inflammatory demyelinating polyneuropathy disclosed by massive nerve root enhancement in CMT1A. Muscle Nerve. 2012;45:451-2.
 
P.19 掲載の参考文献
(1) 神田 隆. 末梢神経の疾患. 医学生・研修医のための神経内科学. 改訂2版. 東京:中外医学社;2014. p.263-308.
 
(2) Pestronk A. Neuropathy:differential diagnosis. Neuromuscular Disease Center. http://neuromuscular.wustl.edu/naltbrain.html(2017年11月15日閲覧).
 
(3) Marsh EA, Llewelyn JG. Multiple mononeuropathies. In:Hilton-Jones D, Turner MR, eds. Oxford textbook of neuromuscular disorders. New York:Oxford University Press;2014. p.115-9.
 
(4) Verhamme C, van Schaik IN. Polyneuropathies:axonal. In:Hilton-Jones D, Turner MR, eds. Oxford textbook of neuromuscular disorders. New York:Oxford University Press;2014. p.132-42.
 
(5) 尾方克久. 血管炎性末梢神経障害の症候学と診断. Brain Nerve. 2016;63:205-11.
 
(6) 厚生労働省難治性疾患等政策研究事業 ライソゾーム病(ファブリー病を含む)に関する調査研究班, 編. ライソゾーム病・ペルオキシソーム病診断の手引き. 東京:診断と治療社;2015.
 
P.24 掲載の参考文献
(1) Guillain G, Barre JA, Strohl A. Sur un syndrome de radiculo-nevrite avec hyperalbuminose du liquide cephalo-rachidien sans reaction cellulaire. Remarques sur les caracteres clin iques et graphiques des reflexes tendineux. Bull mem Soc Med Hop Paris. 1916;40:1462-70.
 
(2) Clinical Question 9-2 ギラン・バレー症候群の診断に蛋白解剖解離は必須か. In:日本神経学会, 監. ギラン・バレー症候群, フィッシャー症候群作成委員会, 編. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:南江堂;2013. p.62.
 
(3) Wong AH, Umapathi T, Nishimoto Y, et al. Cytoalbuminologic dissociation in Asian patients with Guillain-Barre and Miller Fisher syndromes. J Peripher Nerv Syst. 2015;20:47-51.
 
(4) Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 1975;50:621-37.
 
(5) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst. 2010;15:79-92.
 
(6) Clinical Question 4-5 髄液検査の意義はあるか. In:日本神経学会, 監. 慢性炎症性脱髄性多発根ニューロパチー 多巣性運動ニューロパチー診療ガイドライン 2013. 東京:南江堂;2013. p.43.
 
(7) Clinical Question 9-3 脳脊髄液検査で細胞数が正常範囲を超えている場合に考えるべきことは何か. In:日本神経学会, 監. ギラン・バレー症候群, フィッシャー症候群作成委員会, 編. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:南江堂;2013. p.64.
 
P.31 掲載の参考文献
(1) Midroni G, Bilbao JM. Peripheral nerve biopsy and the role of nerve biopsy. In:Biopsy diagnosis of peripheral neuropathy. Boston:Butterworth-Heinemann;1995. p.1-11.
 
(2) 神田 隆. 神経生検の取り扱い. 病理と臨床. 2006;24:1156-9.
 
(3) Sommer CL, Brandner S, Dyck PJ, et al. Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. J Peripher Nerv Syst. 2010;15:164-75.
 
(4) 岡 伸幸, 秋口一郎. 神経生検の適応, 神経生検の手順. In:カラーアトラス末梢神経の病理. 東京:中外医学社;2010. p.8-30.
 
(5) Weis J, Brandner S, Lammens M, et al. Processing of nerve biopsies:a practical guide for neuropathologists. Clin Neuropathol. 2012;31:7-23.
 
P.35 掲載の参考文献
(1) Sugimoto T, Ochi K, Hosomi N, et al. Ultrasonographic reference sizes of the median and ulnar nerves and the cervical nerve roots in healthy Japanese adults. Ultrasound Med Biol. 2013;39:1560-70.
 
(2) Zaidman CM, Al-Lozi M, Pestronk A. Peripheral nerve size in normals and patients with polyneuropathy:an ultrasound study. Muscle Nerve. 2009;40:960-6.
 
(3) Zaidman CM, Pestronk A. Nerve size in chronic inflammatory demyelinating neuropathy varies with disease activity and therapy response over time:a retrospective ultrasound study. Muscle Nerve. 2014;50:733-8.
 
(4) Kerasnoudis A, Pitarokoili K, Behrendt V, et al. Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy. Clin Neurophysiol. 2014;125:635-41.
 
(5) Grimm A, Decard BF, Axer H, et al. The ultrasound pattern sum score- UPSS. A new method to differentiate acute and subacute neuropathies using ultrasound of the peripheral nerves. Clin Neurophysiol. 2015;126:2216-25.
 
(6) Sugimoto T, Ochi K, Hosomi N, et al. Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease:distinction from patients with chronic inflammatory demyelinating polyneuropathy. J Neurol. 2013;260:2580-7.
 
(7) Noto Y, Shiga K, Tsuji Y, et al. Nerve ultrasound depicts peripheral nerve enlargement in patients with genetically distinct Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry. 2015;86:378-84.
 
(8) Misawa S, Noto Y, Shibuya K, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology. 2011;77:1532-7.
 
(9) Nodera H, Takamatsu N, Shimatani Y, et al. Thinning of cervical nerve roots and peripheral nerves in ALS as measured by sonography. Clin Neurophysiol. 2014;125:1906-11.
 
(10) Nodera H, Izumi Y, Takamatsu N, et al. Cervical root sonography to differentiate multifocal motor neuropathy from ALS. J Med Invest. 2016;63:104-7.
 
(11) Noto Y, Shiga K, Tsuji Y, et al. Contrasting echogenicity in flexor digitorum profundus-flexor carpi ulnaris:a diagnostic ultrasound pattern in sporadic inclusion body myositis. Muscle Nerve. 2014;49:745-8.
 
(12) Nodera H, Takamatsu N, Matsui N, et al. Intramuscular dissociation of echogenicity in the triceps surae characterizes sporadic inclusion body myositis. Eur J Neurol. 2016;23:588-96.
 
(13) Nakamori M, Hosomi N, Takaki S, et al. Tongue thickness evaluation using ultrasonography can predict swallowing function in amyotrophic lateral sclerosis patients. Clin Neurophysiol. 2016;127:1669-74.
 
P.42 掲載の参考文献
(1) 末吉健志. MR neurography の臨床応用でわかったこと. 脊椎脊髄. 2016;29:853-9.
 
(2) Yamashita T, Thomas CK. Whole-body magnetic resonance neurography. N Engl J Med. 2009;361:538-9.
 
(3) Shibuya K, Sugiyama A, Ito S, et al. Reconstruction magnetic resonance neurography in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2015;77:333-7.
 
(4) Eurelings M, Notermans NC, Franssen H, et al. MRI of the brachial plexus in polyneuropathy associated with monoclonal gammopathy. Muscle Nerve. 2001;24:1312-8.
 
(5) Sinclair CD, Miranda MA, Cowley P, et al. MRI shows increased sciatic nerve cross sectional area in inherited and inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2011;82:1283-6.
 

II 臨床診断と治療

P.51 掲載の参考文献
(1) Bruce BB, Biousse V, Newman NJ. Third nerve palsies. Semin Neurol. 2007;27:257-68.
 
(2) Warwick R. Representation of the extra-ocular muscles in the oculomotor nuclei of the monkey. J Comp Neurol. 1953;98:449-503.
 
(3) Nagaoka U, Kato T, Kurita K, et al. Cranial nerve enhancement on three-dimensional MRI in Miller Fisher syndrome. Neurology. 1996;47:1601-2
 
P.59 掲載の参考文献
(1) Gonella MC, Fichbein NJ, So YT. Disorders of the trigeminal system. Semin Neurol. 2009;29:36-44.
 
(2) Borges A, Casselman J. Imaging the trigeminal nerve. Eur J Radiol. 2010;74:323-40.
 
(3) Bathla G, Hegde AN. The trigeminal nerve:an illustrated review of its imaging anatomy and pathology. Clin Radiol. 2013;68:203-13.
 
(4) Calverley JR, Mohnac AM. Syndrome of the numb chin. Arch Intern Med. 1963;112:819-21.
 
P.64 掲載の参考文献
(1) 日本神経治療学会治療指針作成委員会, 編. 標準的神経治療:三叉神経痛. 日本神経治療学会;2009.
 
(2) Bajuwa ZH, Ho CC, Kharn SA. Trigeminal neuralgia. Up to Date;2016.
 
(3) Headache Classification Committee of the International Headache Society(IHS). The International Classification of Headache Disorders, 3rd ed(beta version). Cephalalgia. 2013;33:629.
 
(4) Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306-8.
 
(5) Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia:results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443-50.
 
P.68 掲載の参考文献
(1) 村上信五. 顔面神経麻痺の診断と治療. 日耳鼻. 2012;115:118-21.
 
(2) Keane JR. Bilateral seventh nerve palsy:analysis of 43 cases and review of the literature. Neurology. 1994;44:1198-202.
 
(3) 並木聡子, 竹越英樹, 菊地 茂. 両側同時性顔面神経麻痺の2例. 耳鼻臨床. 2003;96:309-12.
 
P.73 掲載の参考文献
(1) 日本神経学会治療指針作成委員会. 標準的神経治療:Bell 麻痺. 神経治療. 2008;25:171-85.
 
(2) 楠 淳一, 斎藤豊和. Bell麻痺にアシクロビルは使用すべきか. In:岡本幸一, 棚橋紀夫, 水澤英洋, 編. EBM 神経疾患の治療 2009-2010. 東京:中外医学社;2009. p.506-11.
 
(3) Hato N, Murakami S, Gyo K. Steroid and antiviral treatment for Bell's palsy. Lancet. 2008;371:1818-20.
 
P.80 掲載の参考文献
(1) 田中靖久, 国分正一. 頚部神経根症と頚部脊髄症の症候による診断. In:越智隆弘, 菊池臣一, 編. NEW MOOK 整形外科 No.6. 頚椎症. 東京:金原出版;1999. p.30-8.
 
(2) Tanaka Y, Kokubun S, Sato T, et al. Cervical roots as origin of pain in the neck and scapular regions. Spine(Phila Pa 1976). 2006;31:E568-73.
 
(3) 園生雅弘. 遠位型頚椎症性筋萎縮症. 臨床神経生理学. 2015;43:99-108.
 
(4) 東原真奈, 園生雅弘.神経痛性筋萎縮症. Peripheral Nerve. 2015;26:203-5.
 
(5) 園生雅弘. 頚椎症と末梢神経障害の鑑別診断-電気生理学的検査を含めて-. Brain Medical. 2013;25:49-55.
 
P.88 掲載の参考文献
(1) 久野木順一. 腰仙部の nerve stretch test. 脊椎脊髄. 2015;28:306-8.
 
(2) 久野木順一. Kempテスト. 脊椎脊髄. 2015;28:309-11.
 
(3) 日本整形外科学会診療ガイドライン委員会, 腰椎椎間板ヘルニア診療ガイドライン策定委員会, 編. 腰椎椎間板ヘルニア診療ガイドライン. 改訂第2版. 東京:南江堂;2011. p.1-94.
 
(4) Al Nezari NH, Schneiders AG, Hendrick PA, et al. Neurological examination of the peripheral nervous system to diagnose lumbar spinal disc herniation with suspected radiculopathy:a systematic review and meta-analysis. Spine J. 2013;13:657-74.
 
(5) 福武敏夫. 下垂足. 脊椎脊髄. 2013;26:733-40.
 
P.95 掲載の参考文献
(1) Adlkofer K, Martini R, Aguzzi A, et al. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice. Nat Genet. 1995;11:274-80.
 
(2) Collins MP, Periquet MI, Mendell JR, et al. Nonsystemic vasculitic neuropathy:insights from a clinical cohort. Neurology. 2003;61:623-30.
 
(3) Collins MP, Kissel JT. Neuropathies with Systemic Vasculitis. In:Dyck PJ, Thomas PK, et al, eds. Peripheral neuropathy. 4th ed. Philadelphia:Elsevier;2005. p.2335-57.
 
(4) Tankisi H, Pugdahl K, Otto M, et al. Misinterpretation of sural nerve conduction studies due to anatomical variation. Clin Neurophysiol. 2014;125:2115-21.
 
P.106 掲載の参考文献
(1) Sabin TD. Classification of peripheral neuropathy:the long and the short of it. Muscle Nerve. 1986;9:711-9.
 
(2) Gorson KC, Ropper AH. Additional causes for distal sensory polyneuropathy in diabetic patients. J Neurol Neurosurg Psychiatry. 2006;77:354-8.
 
(3) Smith AG, Shingleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. Arch Intern Med. 2004;164:1021-5.
 
(4) Rosenberg NR, Slotema CW, Hoogendijk JE, et al. Follow up of patients with signs and symptoms of polyneuropathy not confirmed by electrophysiological studies. J Neurol Neurosurg Psychiatry. 2005;76:879-81.
 
(5) Singer MA, Vernino SA, Wolfe GI. Idiopathic neuropathy:new paradigms, new promise. J Peripher Nerv Syst. 2012;17 Suppl 2:43-9.
 
(6) Zis P, Sarrigiannis PG, Rao, DG, et al. Chronic idiopathic axonal polyneuropathy:a systematic review. J Neurol. 2016:263:1903-10.
 
P.114 掲載の参考文献
(1) Middleton SD, Anakwe RE. Carpal tunnel syndrome. BMJ. 2014;349:g6437.
 
(2) Fowler JR, Cipolli W, Hanson T. A comparison of three diagnostic tests for carpal tunnel syndrome using latent class analysis. J Bone Joint Surg Am. 2015;97:1958-61.
 
(3) Pryse-Phillips WE. Validation of a diagnostic sign in carpal tunnel syndrome. J Neurol Neurosurg Psychiatry. 1984;47:870-2.
 
(4) Burton CL, Chesterton LS, Chen Y, et al. Clinical course and prognostic factors in conservatively managed carpal tunnel syndrome:a systematic review. Arch Phys Med Rehabil. 2016;97:836-52.e1.
 
(5) Kuschner SH, Ebramzadeh E, Johnson D, et al. Tinel's sign and Phalen's test in carpal tunnel syndrome. Orthopedics. 1992;15:1297-302.
 
P.118 掲載の参考文献
(1) Iwatsuki K, Nishikawa K, Chaki M, et al. Comparative responsiveness of the Hand 20 and the DASH-JSSH questionnaires to clinical changes after carpal tunnel release. J Hand Surg Eur. 2014;39:145-51.
 
(2) Verdugo RJ, Salinas RA, Castillo JL, et al. Surgical versus non-surgical treatment for carpal tunnel syndrome(Review). Cochrane Database Syst Rev. 2008;(4):CD001552.
 
(3) Marshall S, Tardif G, Ashworth N. Local corticosteroid injection for carpal tunnel syndrome(Review). Cochrane Database Syst Rev. 2007;(2):CD001554.
 
(4) 日本神経治療学会治療指針作成委員会. 標準的神経治療:手根管症候群. 神経治療. 2008;25:63-84.
 
(5) Vasiliadis HS, Georgoulas P, Shrier I, et al. Endoscopic release for carpal tunnel syndrome. Cochrane Database Syst Rev. 2014;(1):CD008265.
 
P.124 掲載の参考文献
(1) Gilliatt RW, Le Quesne PM, Logue V, et al. Wasting of the hand associated with a cervical rib or band. J Neurol Neurosurg Psychiatry. 1970;33:615-24.
 
(2) Wilbourn AJ. Thoracic outlet syndrome is overdiagnosed. Muscle Nerve. 1999;22:130-6.
 
(3) Ferrante MA. The thoracic outlet syndromes. Muscle Nerve. 2012;45:780-95.
 
(4) Tsao BE, Ferrante MA, Wilbourn AJ, et al. Electrodiagnostic features of true neurogenic thoracic outlet syndrome. Muscle Nerve. 2014;49:724-7.
 
(5) 園生雅弘, 安藤哲朗, 内堀 歩, 他. True neurogenic thoracic outlet syndrome(TOS)の臨床的・電気生理学的特徴. 臨床神経生理学. 2012;40:131-9.
 
(6) Higashihara M, Sonoo M, Tsuji S, et al. Two-step technique to optimize the medial antebrachial cutaneous nerve response. Clin Neurophysiol. 2010;121:712-3.
 
P.132 掲載の参考文献
(1) Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults:a systemic review and meta-analysis. Lancet Neurol. 2015;14:162-73.
 
(2) 日本神経治療学会治療指針作成委員会. 標準的神経治療:慢性疼痛. 神経治療学. 2010;27:591-622.
 
(3) Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision. Eur J Neurol. 2010;17:1113-e88.
 
(4) Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13:485-96.
 
(5) Gilron I, Baron R, Jensen T. Neuropathic pain:principle of diagnosis and treatment. Mayo Clin Proc. 2015;90:532-45.
 
(6) Pickering G, Marcoux M, Chapiro S, et al. An algorithm for neuropathic pain management in older people. Drugs Aging. 2016;33:575-83.
 
P.137 掲載の参考文献
(1) Aminoff MJ, Asbury AK. Numbness, tingling, and sensory loss. In:Longo DL, Kasper DL, Jameson JL, et al, eds. Harrison's principle of internal medicine. 18th ed. New York:McGraw Hill;2011. p.186-91.
 
(2) Cioroiu CM. Pain, numbness, and paresthesias. In:Louis ED, Mayer SA, Rowland LP, eds. Merritt's neurology. 13rd ed. Philadelphia:Wolters Kluwer;2016. p.54-9.
 
(3) Brannagan III TH. Neuropathic Pain. In:Louis ED, Mayer SA, Rowland LP, eds. Merritt's neurology. 13rd ed. Philadelphia:Wolters Kluwer;2016. p.462-7.
 
P.142 掲載の参考文献
(1) Yokota T, Hayashi M, Hirashima F, et al. Dysautonomia with acute sensory motor neuropathy. A new classification of acute autonomic neuropathy. Arch Neurol. 1994;51:1022-31.
 
(2) Gibbons GH, Vernino SA, Freeman R. Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. Arch Neurol. 2008;65:213-7.
 
(3) Hayashi M, Ishii Y. A case of autoimmune autonomic ganglionopathy(AAG)and a review of AAG cases in Japan. Auton Neurosci. 2009;146:26-8.
 
P.148 掲載の参考文献
(1) 中村利孝, 松野丈夫, 井樋栄二, 他. 第38章 末梢神経損傷. In:内田淳正, 監. 標準整形外科. 第11版. 東京:医学書院;2011. p.810-829.
 
(2) 田島文博, 中村 健, 西村行秀, 他. CMTのリハビリテーション. Brain Nerve.2016;68:59-68.
 
(3) 日本神経学会, 監修. 慢性炎症性脱髄性多発根ニューロパチー, 多巣性ニューロパチー診療ガイドライン 2013. p.2-28.
 
(4) 日本糖尿病学会. 科学的根拠に基づく糖尿病診療ガイドライン 2016. 4 運動療法. p.41-51.
 
(5) 水間正澄. リハビリテーションのアプローチ(1)運動療法. J Clin Rehabil. 2007;16:129-34.
 

III 遺伝性末梢神経障害

P.157 掲載の参考文献
(1) Murakami T, Garcia CA, Reiter LT, et al. Charcot-Marie-Tooth disease and related inherited neuropathies. Medicine. 1996;75:233-50.
 
(2) Abe A, Numakura C, Kijima K, et al. Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. J Hum Genet. 2011;56:364-8.
 
(3) Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010;13:1181-91.
 
(4) Murakami T, Kutoku Y, Nishimura H, et al. Mild phenotype of Charcot-Marie-Tooth disease type 4B1. J Neurol Sci. 2013;334:176-9.
 
(5) Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. Ann Neurol. 2016;79:659-72.
 
(6) Bennett DLH, Woods CG. Painful and painless channelopathies. Lancet Neurol. 2014;13:587-99.
 
P.167 掲載の参考文献
(1) Timmerman V, Strickland AV, Zuchner S, et al. Genetics of Charcot-Marie-Tooth(CMT)disease within the frame of the Human Genome Project success. Genes(Basel). 2014;5:13-32.
 
(2) Rossor AM, Polke JM, Houlden H, et al. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9:562-71.
 
(3) Chance PF. Inherited focal, episodic neuropathies:hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy. Neuromolecular Med. 2006;8:159-74.
 
(4) Abe A, Numakura C, Hayasaka K, et al. Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. J Hum Genet. 2011;56:364-8.
 
(5) Higuchi Y, Hashiguchi A, Takashima H, et al. Mutations in MME cause an autosomal-recessive Charcot-Marie-Tooth disease type 2. Ann Neurol. 2016;79:659-72.
 
P.172 掲載の参考文献
(1) 渡邉耕太, 山下敏彦, 和田郁雄. CMTの手術療法・術後後療法. In:CMT診療マニュアル編集委員会, 編. シャルコー・マリー・トゥース病診療マニュアル. 改訂第2版. 京都:金芳堂;2015. p.107-22.
 
(2) Herring JA. Tachdjian's pediatric orthopaedics. 5th ed. Philadelphia:Saunders;2014. p.834-83.
 
(3) Guyton GP. Current concepts review:orthopaedic aspects of Charcot-Marie-Tooth disease. Foot Ankle Int. 2006;27:1003-10.
 
(4) Karol LA, Elerson E. Scoliosis in patients with Charcot-Marie-Tooth disease. J Bone Joint Surg. 2007;89A:1504-10.
 
P.179 掲載の参考文献
(1) Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057-62.
 
(2) Koike H, Misu K, Ikeda S, et al. Study group for hereditary neuropathy in Japan:type I(transthyretin Met30)familial amyloid polyneuropathy in Japan:early- vs late-onset form. Arch Neurol. 2002;59:1771-6.
 
(3) Ikeda S, Nakazato M, Ando Y, et al. Familial transthyretin-type amyloid polyneuropathy in Japan:clinical and genetic heterogeneity. Neurology. 2002;58:1001-7.
 
(4) Koike H, Hashimoto R, Tomita M, et al. Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy:a practical analysis. Amyloid. 2011;18:53-62.
 
(5) Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31-46.
 
(6) Masuda T, Ueda M, Suenaga G, et al. Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy. Neurology. 2017;88:2192-7.
 
P.185 掲載の参考文献
(1) Ando Y, Nakamura M, Araki S, et al. Transthyretin-ralated familial amyloidotic polyneuropathy. Arch Neurol. 2005;62:1057-62.
 
(2) Palnte-Bardeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086-97.
 
(3) アミロイドーシスの調査研究班. アミロイドーシス診療ガイドライン 2010. p.20-6.
 
(4) Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2012;29(suppl 1):S14-26.
 
(5) Ericzon BG, Wilczec HE, Larsson M, et al. Liver transplantation for hereditary transthyretin amyloidosis:after 20 years still the best therapeutic alternative? Transplantation. 2015;99:1847-54.
 
(6) Ohya Y, Okamoto S, Tasaki M, et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy:long-term follw-up of Japanese patients after liver transplantation. Surg Today. 2011;41:1211-8.
 
(7) Hara R, Kawaji T, Ando E, et al. Impact of liver transplantation on transthyretin-related ocular amyloidosis in Japanese patients. Arch Opthalmol. 2010;128:206-10.
 
(8) Sandgren O, Kjellgren D, Suhr OB. Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy. Acta Opthalmol. 2008;86:520-4.
 
(9) Maia LF, Magalhaes R, Freitas J, et al. CNS involvement in V30M transthyretin amyloidosis:clinical, neuropathological and biochemical findings. J Neurol Neurosurg Psychiatry. 2015;86:159-67.
 
(10) Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121:73-85.
 
(11) Sekijima Y. Recent progress in the understanding and treatment of transthyretin amyloidosis. J Clin Pharm Therapeutics. 2014;39:225-33.
 
(12) Bulawa CE, Connelly S, Devit M, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629-34.
 
(13) de Lartigue J. Tafamidis for transthyretin amyloidosis. Drugs Today(Barc). 2012;48:331-7.
 
(14) Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy:a randomized, controlled trial. Neurology. 2012;79:785-92.
 
(15) Hammarstorm P, Wiseman RL, Powers ET, et al. Prevention of transthyretin amyloid disease by changing protein misfolding energetic. Science. 2003;299:713-6.
 
(16) Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. 2004;84:545-52.
 
(17) Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid polyneuropathy:a randomized clinical trial. JAMA. 2013;310:2658-67.
 
(18) Takahashi R, Ono K, Shibata S, et al. Efficacy of diflunisal on autonomic dysfunction of late-onset familial amyloid polyneuropathy(TTR Val30Met)in a Japanese endemic area. J Neurol Sci. 2014;345:231-5.
 
(19) 安東由喜雄. 家族性アミロイドポリニューロパチー. In:山田正仁, 編. アミロイドーシス-診療のすべて. 東京:医歯薬出版;2011. p.71-86.
 
(20) Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Translational Neurodegeneration. 2014;3:19.
 
(21) Sant'Anna R, Gallego P, Robinson LZ, et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun. 2016;7:10787.
 
P.193 掲載の参考文献
(1) Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16.
 
(2) Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events:natural history data from the Fabry Registry. Stroke. 2009;40:788-94.
 
(3) Mehta A, Ricci R, Widmer U, et al. Fabry disease defined:baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34:236-42.
 
(4) Kaye EM, Kolodny EH, Logigian EL, et al. Nervous system involvement in Fabry's disease:clinicopathological and biochemical correlation. Ann Neurol. 1988;23:505-9.
 
(5) Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy-a retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23:535-42.
 
P.199 掲載の参考文献
(1) 神経変性疾患領域における基盤的調査研究班. 神経有棘赤血球症の診断基準. http://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000089917.pdf2.3.4.5.
 
(2) 水澤英洋, 他. 神経症候群(第2版)日本臨牀別冊 神経症候群. 2版. 大阪:日本臨牀社;2014.
 
(3) Matsuzono K, Ikeda Y, Liu W, et al. A novel familial prion disease causing pan-autonomic-sensory neuropathy and cognitive impairment. Eur J Neurol. 2013;20:e67-9.
 
(4) Mead S, Gandhi S, Beck J, et al. A novel prion disease associated with diarrhea and autonomic neuropathy. N Engl J Med. 2013;369:1904-14.
 
(5) 松薗構佑, 阿部康二. 中枢神経感染症のトピックス-最新の話題と課題. プリオン病とslow virus感染. Mebio. 2016;33:31-41.
 
P.203 掲載の参考文献
(1) Sekijima Y. Transthyretin(ATTR)amyloidosis:clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036-43.
 
(2) Plante-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy(TTR-FAP). Neurology. 2007;69:693-8.
 
(3) 関島良樹. 家族性アミロイドポリニューロパチー:新規薬物療法(ジフルニサルとタファミジス). Brain Nerve.2014;66:773-81.
 
(4) Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy:a randomized, controlled trial. Neurology. 2012;79:785-92.
 
(5) Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819-29.
 
(6) Sekijima Y, Yazaki M, Oguchi K, et al. Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis. Neurology. 2016;87:773-81.
 

IV 代謝性・中毒性末梢神経障害

P.211 掲載の参考文献
(1) Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy:a review. JAMA. 2015;314:2172-81.
 
(2) Burns TM, Mauermann ML. The evaluation of polyneuropathies. Neurology. 2011;76:S6-13.
 
(3) Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency:a guide for the primary care physician. Arch Intern Med. 1999;159:1289-98.
 
(4) Alamdari A, Mozafari R, Tafakhori A, et al. An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects. Neurol Sci. 2015;36:1121-6.
 
P.218 掲載の参考文献
(1) 有村公良, 出口尚寿. 神経・精神疾患診療マニュアル. よくみられる神経疾患 糖尿病. 日医師会誌. 2013;142:S242-4.
 
(2) Chan AC, Wilder-Smith EP. Small fiber neuropathy:getting bigger! Muscle Nerve. 2016;53:671-82.
 
(3) Pasnoor M, Dimachkie MM, Barohn RJ. Diabetic neuropathy part 2:proximal and asymmetric phenotypes. Neurol Clin. 2013;31:447-62.
 
(4) Tran C, Philippe J, Ochsner F, et al. Acute painful diabetic neuropathy:an uncommon, remittent type of acute distal small fibre neuropathy. Swiss Med Wkly. 2015;145:w14131.
 
(5) Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. J Diabetes Complications. 2016;30:1401-7.
 
(6) Mustapa A, Justine M, Mohd Mustafah N, et al. Postural control and gait performance in the diabetic peripheral neuropathy:a systematic review. Biomed Res Int. 2016;2016:9305025.
 
P.225 掲載の参考文献
(1) Yagihashi S, Yamagishi S, Wada R. Pathology and pathogenetic mechanisms of diabetic neuropathy:correlation with clinical signs and symptoms. Diabe Res Clin Pract. 2007;77:S184-9.
 
(2) Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352:341-50.
 
(3) Hotta N, Akanuma Y, Kawamori R, et al. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy:the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care. 2006;29:1538-44.
 
(4) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ, 編. 神経障害性疼痛薬物療法ガイドライン改訂. 第2版. 東京:真興交易医書出版部;2016. p.48-100.
 
(5) 出口尚寿, 西尾善彦. 糖尿病神経障害の最近の進歩 4. 対症療法. 糖尿病. 2014;57:602-5.
 
(6) Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin:high-dose monotherapy or their combination? The "COMBO-DN study" a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154:2616-25.
 
(7) Himeno T, Kamiya H, Naruse K, et al. Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes. 2011;60:2397-406.
 
P.229 掲載の参考文献
(1) Koike H, Misu K, Hattori N, et al. Postgastrectomy polyneuropathy with thiamine deficiency. J Neurol Neurosurg Psychiatry. 2001;71:357-62.
 
(2) Koike H, Iijima M, Sugiura M, et al. Alcoholic neuropathy is clinicopahthologically distinct form thiamine-deficiency neuropathy. Ann Neurol. 2003;54:19-29.
 
(3) Koike H, Takahashi M, Ohyama K, et al. Clinicopathologic features of folate-deficiency neuropathy. Neurology. 2015;84:1026-33.
 
(4) Koike H, Ito S, Morozumi S, et al. Rapidly developing weakness mimicking Guillain-Barre syndrome in beriberi neuropathy:two case reports. Nutrition. 2008;24:776-80.
 
(5) Koike H, Watanabe H, Inukai A, et al. Myopathy in thiamine deficiency:analysis of a case. J Neurol Sci. 2006;249:175-9.
 
(6) Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology. 2001;56:1727-32.
 
P.234 掲載の参考文献
(1) 坂井 公, 中嶋義明, 森田陽子, 他. 低濃度 n-ヘキサン暴露の指標としての遊離および総2,5-ヘキサンジオンの有用性. 日職災医誌. 2004;52:308-14.
 
(2) 高田良治, 白石匡史, 松浦英治, 他. 慢性炎症性脱髄性多発ニューロパチーとの鑑別を要したn-ヘキサン中毒性多発ニューロパチーの1例. 日内会誌. 2006;95:933-5.
 
(3) 橋詰 淳, 川頭祐一, 伊藤瑞規, 他. MRSにて中枢の脱髄を認めた n-Hexane による末梢神経障害の1例. 臨床神経. 2009;49:217(抄録).
 
(4) 右近紳一郎, 渡邊将平, 末永浩一, 他. 亜急性に進行する四肢筋力低下を呈した n-ヘキサン中毒性ニューロパチーの1例. 臨床神経学. 2014;54:598(抄録).
 
(5) 木田博隆, 成田有吾, 葛原茂樹. 液晶画面洗浄工場で集団発生したノルマルヘキサン中毒の検討. 産衛誌. 2004;46:99-100.
 
P.238 掲載の参考文献
(1) Le Quesne PM, McLeod JG. Peripheral neuropathy following a single exposure to arsenic. Clinical course in four patients with electrophysiological and histological studies. J Neurol Sci. 1977;32:437-51.
 
(2) Hafeman DM, Ahsan H, Louis ED, et al. Association between arsenic exposure and measure of subclinical sensory neuropathy in Bangladesh. J Occup Environ Med. 2005;47:778-84.
 
(3) Goddard MJ, Tanhehco JL, Dau PC. Chronic arsenic poisoning masquerading as Landry-Guillain-Barre syndrome. Electromyogr Clin Neurophysiol. 1992;32:419-23.
 
(4) Vahidnia A, van der Voet GB, de Wolff FA. Arsenic neurotoxicity-a review. Hum Exp Toxicol. 2007;26:823-32.
 
(5) Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003;79:391-6.
 
(6) Chowdhury R, Dutta A, Chaudhuri SR, et al. In vitro and in vivo reduction of sodium arsenite anduced toxicity by aqueous garlic extract. Food Chem Toxicol. 2008;46:740-51.
 
P.247 掲載の参考文献
(1) Jain KK. Drug-induced peripheral neuropathies. In:Jain KK, ed. Drug-induced neurological disorders. 2nd ed. Seattle:Hogrefe & Huber;2001. p.263-94.
 
(2) Foley C, Schofield I, Eglon G, et al. Charcot-Marie-Tooth disease in Northen England. J Neurol Neurosurg Psychiatry. 2012;83:572-3.
 
(3) Kurihara S, Adachi Y, Wada K, et al. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan. Neuroepidemiology. 2002;21:246-50.
 
(4) Graf WD, Chance PF, Lensch MW, et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996;77:1356-62.
 
(5) Ralph N, Johannes M, Ulrike R, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol. 2011;115:323-5.
 
(6) Mercuri E, Poulton J, Buck J, et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child. 1999;81:442-3.
 
(7) Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology. 1969;19:367-74.
 
(8) Casey EB, Jellife AM, Le Quesne PM, et al. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96:69-86.
 
(9) Vilholm JO, Christensen AA, Zedan HA, et al. Drug-induced peripheral neuropathy. Basic Clin Pharmacol Toxicol. 2014;115:185-92.
 
(10) Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006;24:1633-42.
 
(11) Van der Hoop RG, van der Burg ME, ten Bokkel Huinink WW, et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 1990;66:1697-702.
 
(12) Gurney H, Crowther D, Anderson H, et al. Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma. Ann Oncol. 1990;1:427-33.
 
(13) Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature. Blood. 2008;112:1593-9.
 
(14) Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy:a ganglionopathy? Neurology. 2003;60:877-8.
 
(15) Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008;13:275-82.
 
(16) Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24:655-67.
 
(17) Tan CH, Chen YF, Chen CC, et al. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry. 2011;82:462-5.
 
(18) Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Inf Dis Suppl. 1981;26:60-7.
 
(19) Tan I, Polydefkis J, Ebenezer G, et al. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol. 2012;69:265-8.
 
(20) Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals:risk factors, incidence and management. Drug Saf. 1998;19:481-94.
 
(21) Iwamoto T, Ishibashi M, Fujieda A, et al. Drug interaction between itraconazole and bortezomib:exacerbation of peripheral neuropathy and thrombocytopenia induced by bortezomib. Pharmacotherapy. 2010;30:661-5.
 
(22) Baxter CG, Marshall A, Roberts M, et al. Peripheral neuropathy in patients on long-term triazole antifungal therapy. J Antimicrob Chemother. 2011;66:2136-9.
 
(23) Stubgen JP. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve. 2008;37:81-292.
 
(24) Kato-Motozaki Y, Komai K, Takahashi K, et al. Polyethylene glycol interferon alpha-2b-induced immune-mediated polyradiculoneuropathy. Intern Med. 2009;48:569-72.
 
(25) Shiga K, Tanaka E, Isayama R, et al. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon α-2b:a neuropathology case report. Intern Med. 2012;51:217-21.
 
(26) Bharadwaj A, Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology. 2004;43:934.
 
(27) Bhagavati S, Maccabee P, Muntean E, et al. Chronic sensorimotor polyneuropathy associated with tacrolimus immunosuppression in renal transplant patients:case reports. Transplant Proc. 2007;39:3465-7.
 
(28) Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy. Neurology. 2002;58:1333-7.
 
(29) Corrao G, Zambon A, Bertu L, et al. Lipid-lowering drugs prescription and the risk of peripheral neuropathy an exploratory case-control study using automated databases. J Epidemiol Community Health. 2004;58:1047-51.
 
(30) de Langen JJ, van Puijenbroek EP. HMG-CoA-reductase inhibitors and neuropathy:reports to the Netherlands Pharmacovigilance Centre. Neth J Med. 2006;64:334-8.
 
(31) Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med. 2000;160:1741-8.
 
(32) Jacobs JM, Costa-Jussa FR. The pathology of amiodarone neurotoxicity. II. Peripheral neuropathy in man. Brain. 1985;108:753-69.
 
(33) Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic parkinson disease. Ann Neurol. 2010;67:28-36.
 
(34) Rajabelly A, Martey J. Neuropathy in Parkinson disease. Neurology. 2011;77:1947-50.
 

V 自己免疫性末梢神経障害

P.260 掲載の参考文献
(1) Schroder JM. Pathology of peripheral nerves:an atlas of structural and molecular pathological changes. Springer;2001.
 
(2) Bilbao J, Schmidt RE. Biopsy diagnosis of peripheral neuropathy. 2nd ed. Springer;2015.
 
P.270 掲載の参考文献
(1) Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol. 1990;27(suppl):S21-4.
 
(2) Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain. 1995;118:597-605.
 
(3) Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barre syndrome:clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol. 1998;44:780-8.
 
(4) 日本神経学会, 監. 「ギラン・バレー症候群, フィッシャー症候群診療ガイドライン」作成委員会, 編. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:南江堂;2013. p.14-80.
 
(5) Hugh JW, Bart CJ, Pieter AVD. Guillain-Barre syndrome. Lancet. 2016;388:717-27.
 
(6) McGrogan A, Madle GC, Seaman HE, et al. The epidemiology of Guillain-Barre syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32:150-63.
 
(7) 斎藤豊和, 他. Guillain-Barre 症候群全国疫学調査第一次アンケート調査の結果報告. 厚生省特定疾患 免疫性神経疾患調査研究分科会 平成10年度研究報告書;1999. p.59-60.
 
(8) 荻野美恵子, 他. Guillain-Barre 症候群の全国調査-第3次調査を含めた最終報告-. 厚生労働省特定疾患対策研究事業 免疫性神経疾患に関する調査研究班 平成12年度研究報告書;2001. p.99-101.
 
(9) Kanda T, Hayashi H, Tanabe H, et al. A fulminant case of Guillain-Barre syndrome:topographic and fibre size related analysis of demyelinating changes. J Neurol Neurosurg Psychiatry. 1989;52:857-64.
 
(10) Winer JE, Hughes RA, Greenwood RJ, et al. Prognosis in Guillain-Barre syndrome. Lancet. 1985;1;1202-3.
 
(11) van Koningsveld R, Steyerberg EW, Hughes RA, et al. A clinical prognostic scoring system for Guillain-Barre syndrome. Lancet Neurol. 2007;6:589-94.
 
(12) Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guil-lain-Barre syndrome. Ann Neurol. 2010;67:781-7.
 
(13) Kuwabara S, Asahina M, Koga M, et al. Two patterns of clinical recovery in Guillain-Barre syndrome with IgG anti-GM1 antibody. Neurology. 1998;51:1656-60.
 
(14) Ho TW, Li CY, Cornblath DR, et al. Patterns of recovery in the Guillain-Barre syndromes. Neurology. 1997;48:695-700.
 
(15) Kuwabara S, Ogawara K, Misawa S, et al. Sensory nerve conduction in demyelinating and axonal Guillain-Barre syndrome. Eur Neurol. 2004;51:196-8.
 
(16) Kawakami S, Sonoo M, Kadoya A, et al. A-waves in Guillain-Barre syndrome:correlation with electrophysiological subtypes and antiganglioside antibodies. Clin Neurophysiol. 2012;123:1234-41.
 
P.277 掲載の参考文献
(1) 「ギラン・バレー, フィッシャー症候群診療ガイドライン」作成委員会. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:南江堂;2013. p.38-9.
 
(2) Wakerley BR, Yuki N. Mimics and chameleons in Guillain-Barre and Miller Fisher syndromes. Pract Neurol. 2015;15:90-9.
 
(3) Dubey D, Kapotic M, Freeman M, et al. Factors contributing to delay in diagnosis of Guillain-Barre syndrome and impact on clinical outcome. Muscle Nerve. 2016;53:384-7.
 
(4) Dionne A, Nicolle MW, Hahn AF. Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve. 2010;41:202-7.
 
(5) 角谷真人, 尾上祐行, 角谷彰子, 他. 小脳性運動失調と顔面感覚障害を合併した wall-eyed bilateral internuclear ophthalmoplegia(WEBINO)症候群の85歳男性例. 臨床神経. 2014;54:317-20.
 
(6) Caplan LR. Fisher's Rules. Arch Neurol. 1982;39:389-90.
 
P.280 掲載の参考文献
(1) Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115-26.
 
(2) Griffin JW, Li CY, Ho TW, et al. Guillain-Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118:577-95.
 
(3) Kuwabara S, Yuki N. Axonal Guillain-Barre syndrome:concepts and controversies. Lancet Neurol. 2013;12:1180-8.
 
(4) Hiraga A, Mori M, Ogawara K, et al. Differences in patterns of progression in demyelinating and axonal Guillain-Barre syndromes. Neurology. 2003;61:471-4.
 
(5) Asahina M, Kuwabara S, Suzuki A, et al. Autonomic function in demyelinating and axonal subtypes of Guillain-Barre syndrome. Acta Neurol Scand. 2002;105:44-50.
 
P.286 掲載の参考文献
(1) Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. Lancet. 2016;388:717-27.
 
(2) 「ギラン・バレー症候群, フィッシャー症候群診療ガイドライン」作成委員会, 編. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:南江堂;2013.
 
(3) Tagawa Y, Yuki N, Hirata K. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption. J Neurol Sci. 1998;157:90-5.
 
(4) Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome. Ann Neurol. 2009;66:597-603.
 
(5) Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet. 1997;349:225-30.
 
(6) Misawa S, Kuwabara S, Sekiguchi Y, et al. Eculizumab for Guillain-Barre syndrome:Randomized clinical trial(JET-GBS study). XXIII World Congress of Neurology(Abstract). http://cmoffice.kenes.com/WCN17/CM.NET.WebUI/CM.NET.WEBUI.scpr/SCPRsessions2.aspx?conferenceid=05000000-0000-0000-0000-000000000217&sessionID=05000000-0000-0000-0000-000000049293
 
P.296 掲載の参考文献
(1) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy:report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 2010;15:1-9.
 
(2) 日本神経学会慢性炎症性脱髄性多発根ニューロパチー・多巣性運動ニューロパチー診療ガイドライン作成委員会, 編. 慢性炎症性脱髄性多発根ニューロパチー・多巣性運動ニューロパチー診療ガイドライン 2013. 東京:南江堂;2013.
 
(3) Ruts L, Drenthen J, Jacobs BC, et al. Distinguishing acute-onset CIDP from fluctuating Guillan-Barre syndrome:a prospective study. Neurology. 2010;74:1680-6.
 
(4) 神田 隆. 自己免疫性ニューロパチーの診断と治療. 日内会誌. 2017;106:2439-45.
 
(5) Latov N. Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol. 2014;10:435-46.
 
P.303 掲載の参考文献
(1) Rison RA, Beydoun SR. Paraproteinemic neuropathy:a practical review. BMC Neurol. 2016;16:13.
 
(2) Raheja D, Specht C, Simmons Z. Paraproteinemic neuropathies. Muscle Nerve. 2015;51:1-13.
 
(3) Rojas-Garcia R, Gallardo E, Illa I. Paraproteinemic neuropathies. Presse Med. 2013;42:e225-34.
 
(4) Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012;12:102-10.
 
(5) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst. 2010;15:185-95.
 
P.310 掲載の参考文献
(1) 日本神経学会, 監. 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン作成委員会, 編. 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013. 東京:南江堂;2013.
 
(2) Nodera H, Bostock H, Izumi Y, et al. Activity-dependent conduction block in multifocal motor neuropathy:magnetic fatigue test. Neurology. 2006;67:280-7.
 
(3) de Carvalho M, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497-503.
 
(4) Grimm A, Decard BF, Athannasopoulou I, et al. Nerve ultrasound for differentiation between amyotrophic lateral sclerosis and multifocal motor neuropathy. J Neurol. 2015;262:870-80.
 
(5) Kerasnoudis A. Pitarokoili K, Behrendt V, et al. Multifocal motor neuropathy:correlation of nerve ultrasound, electrophysiological, and clinical findirgs. J Peribher Nerv sxst. 2014;19:165-74.
 
(6) Meucci N, Nobile-orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis. J Neurol. 1996;243:117-20.
 
P.318 掲載の参考文献
(1) 日本神経学会, 監修. 「慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン」作成委員会, 編. 慢性炎症性脱髄性多発根ニューロパチー・多巣性運動ニューロパチー診療ガイドライン 2013. 東京:南江堂;2013.
 
(2) Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy(CIDP):an overview of systematic reviews. Cochrane Database Syst Rev. 20173;1:CD010369.
 
(3) Mahdi-Rogers M, Brassington R, Gunn AA, et al. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017;5:CD003280.
 
(4) Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy:report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst. 2010;15:1-9. Erratum in:J Peripher Nerv Syst. 2010;15:373.
 
(5) Delmont E, Manso C, Querol L, et al. Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. Brain. 2017. [Epub ahead of print]
 
(6) Adrichem ME, Eftimov F, van Schaik IN. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. J Peripher Nerv Syst. 2016;21:121-7.
 
P.324 掲載の参考文献
(1) 日本神経学会, 監. 「慢性炎症性脱髄性多発根ニューロパチー, 多巣運動ニューロパチー診療ガイドライン」作成委員会, 編. 慢性炎症性脱髄性多発根ニューロパチー, 多巣性運動ニューロパチー診療ガイドライン 2013. 東京:南江堂;2013.
 
(2) Joint Task Force of the EFNS and the PNS1. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst. 2010;15:295-301.
 
(3) Delmont E, Azulay JP, Giorgi R, et al. Multifocal motor neuropathy with and without conduction block:a single entity? Neurology. 2006;67:592-6.
 
(4) Akaza M, Kanouchi T, Inaba A, et al. Motor nerve conduction study in cauda equina with high-voltage electrical stimulation in multifocal motor neuropathy and amyotrophic lateral sclerosis. Muscle Nerve. 2011;43:274-82.
 
P.328 掲載の参考文献
(1) Kuwabara S, Dispenzieri A, Arimura K, et al. Treatment for POEMS(polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes)syndrome. Cochrane Database Syst Rev. 2012;6:CD006828.
 
(2) Nasu S, Misawa S, Sekiguchi Y, et al. Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2012;83:476-9.
 
(3) Isose S, Misawa S, Kanai K, et al. POEMS syndrome with Guillan-Barre syndrome-like acute onset:a case report and review of neurological progression in 30 cases. J Neurol Neurosurg Psychiatry. 2011;82:678-80.
 
(4) Misawa S, Kuwabara S. Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes(Crow-Fukase)syndrome:diagnostic criteria and treatment perspectives. Clin Exp Neuroimmunol. 2013;4:318-5.
 
(5) Misawa S, Sato Y, Katayama K, et al;Japanese POEMS Syndrome for Thalidomide(J-POST)Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome:a multicentre, randomised, double-blind, placebo controlled trial. Lancet Neurol. 2016;15:1129-37.
 
P.333 掲載の参考文献
(1) Chiba A. Fisher syndrome. In:Kusunoki S, ed. Neuroimmunological Diseases. Springer;2016. p.187-202.
 
(2) Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001;56:1104-6.
 
(3) Mori M, Kuwabara S, Fukutake T, et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology. 2007;68:1144-6.
 
(4) Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007:CD004761.
 
(5) ギラン・バレー症候群, フィッシャー症候群診療ガイドライン作成委員会, 編. ギラン・バレー症候群, フィッシャー症候群診療ガイドライン 2013. 東京:医学書院;2013.
 
(6) Uchibori A, Gyohda A, Chiba A. Ca2+-dependent anti-GQ1b antibody in GQ1b-seronegative Fisher syndrome and related disorders. J Neuroimmunol. 2016;298:172-7.
 
P.339 掲載の参考文献
(1) van Alfen N, van Engelen BG. The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2006;129:438-50.
 
(2) Beghi E, Kurland LT, Mulder DW, et al. Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981. Ann Neurol. 1985;18:320-3.
 
(3) van Alfen N. Clinical and pathophysiological concepts of neuralgic amyotrophy. Nat Rev Neurol. 2011;7:315-22.
 
(4) van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy(brachial neuritis). Cochrane Database Syst Rev. 2009;CD006976.
 
(5) Naito K, Fukushima K, Suzuki S, et al. Intravenous immunoglobulin(IVIg)with methyl predonisolone pulse therapy for motor impairment of neuralgic amyotrophy:clinical observations in 10 cases. Intern Med. 2012;51:1493-500.
 
P.345 掲載の参考文献
(1) Nagano A. Spontaneous anterior interosseous nerve palsy. J Bone Joint Surg Br. 2003;85:313-8.
 
(2) Ochi K, Horiuchi Y, Tazaki K, et al. Surgical treatment of spontaneous posterior interosseous nerve palsy:a retrospective study of 50 cases. J Bone Joint Surg Br. 2011;93:217-22.
 
(3) 越智健介, 加藤博之. 特発性前骨間神経麻痺と特発性後骨間神経麻痺の病態解明と治療方針確立の試み-Neuralgic amyotrophy として保存すべきか否か. Brain Nerve.2014;66:1441-52.
 
(4) 山本真一, 田尻康人, 三上容司, 他.特発性前骨間神経麻痺の手術適応. 日手外科会誌. 2010;26:76-8.
 
(5) Ochi K, Horiuchi Y, Tazaki K, et al. Fascicular constrictions in patients with spontaneous palsy of the anterior interosseous nerve and the posterior interosseous nerve. J Plast Surg Hand Surg. 2012;46:19-24.
 

VI 内科疾患に伴う末梢神経障害

P.359 掲載の参考文献
(1) Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.
 
(2) 厚労省難治性疾患克服研究事業・難治性血管炎に関する調査研究班・進行性腎障害に関する調査研究班. ANCA関連血管炎の診療ガイドライン(2014年改訂版).
 
(3) 厚生労働科学研究費補助金・難治性疾患克服研究事業, 編. ANCA関連血管炎診療ガイドライン 2017. 東京:診断と治療社;2017.
 
(4) Kissel JT, Reithman JL, Omerza J, et al. Peripheral nerve vasculitis:immune characterization of the vascular lesions. Ann Neurol. 1989;25:291-7.
 
(5) Said G, Lacroix-Ciaudo C, Fujimura H, et al. The peripheral neuropathy of necrotizing arteritis:a clinicopathological study. Ann Neurol. 1996;23:461-5.
 
(6) Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-5.
 
P.365 掲載の参考文献
(1) 古賀道明. 血管炎性末梢神経障害のevidence-based treatment.Brain Nerve. 2016;68:243-51.
 
(2) Collins MP, Dyck PJ, Gronseth GS, et al. Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy:executive summary. J Peripher Nerv Syst. 2010;15:176-84.
 
(3) Hattori N, Ichimura M, Nagamatsu M, et al. Clinicopathological features of Churg-Strauss syndrome-associated neuropathy. Brain. 1999;122:427-39.
 
(4) Collins MP, Periguet MI, Mendell JR, et al. Nonsystemic vasculitic neuropathy:insights from a clinical cohort. Neurology. 2003;61:623-30.
 
(5) Koike H, Akiyama K, Saito G. Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis(Churg-Strauss syndrome):a multicenter, double-blind trial. J Neurol. 2015;262:752-9.
 
(6) Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005;1051:779-86.
 
(7) Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417-27.
 
P.370 掲載の参考文献
(1) 古賀道明. サルコイドニューロパチー. Brain Nerve. 2014;66:981-5.
 
(2) 大矢 寧. サルコイドニューロパチー. Peripheral Nerve. 2015;26:39-47.
 
(3) 折津 愈. 神経サルコイドーシスの診断と治療. 日胸疾会誌. 2003;62:608-15.
 
(4) 岡 伸幸, 秋口一郎. 腫瘍性疾患とその他のニューロパチー. Clinician. 2007;561:76-7.
 
(5) 西山和利, 作田 学. 難治性疾患としてのサルコイドーシスの神経・筋病変. 日サ会誌. 2007;27:37-42.
 
P.374 掲載の参考文献
(1) Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. Brain. 2005;128:2518-34.
 
(2) Goransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjogren syndrome. Arch Neurol. 2006;63:1612-5.
 
(3) 住田孝之, 江口勝美, 監. シェーグレン症候群の診断と治療マニュアル. 東京:診断と治療社. 2009. p.127-31.
 
(4) 森 恵子, 祖父江 元. 膠原病・類縁疾患に伴う神経・筋障害の診断と治療～Sjogren 症候群～. 日内会誌, 2010;99:14-22.
 
(5) 住田孝之. シェーグレン症候群. 臨牀と研究. 2010;87:1225-30.
 
P.378 掲載の参考文献
(1) Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol. 2013;175:336-48.
 
(2) Giometto B, Vitaliani R, Briani C. Paraneoplastic disorders of the peripheral nervous system. In:Grisold W, Soffietti R, eds. Handbook of Clinical Neurology. 105(3rd series). Elsevier;2012. Ch. 56, p.865-70.
 
P.383 掲載の参考文献
(1) 神経系の悪性リンパ腫 update. Brain Nerve. 2014;66(8).
 
(2) 須貝章弘, 今野卓哉, 矢野俊男, 他. 両側舌萎縮で発症した神経リンパ腫症の1例. 臨床神経. 2012;52:589-91.
 
P.387 掲載の参考文献
(1) Sabin TD, Swift TR. Leprosy. In:Dyck PJ, Lambert EH, eds. Philadelphia:Saunders;1975. p.1166-98.
 
(2) 岩田 誠. 神経症候学を学ぶ人のために. 東京:医学書院;2004. p.285-6.
 
(3) 岩田 誠. ハンセン病における末梢神経障害. In:大谷藤郎, 監修. 総説現代ハンセン病医学. 東京:東海大学出版会;2007. p.228-40.
 
(4) 岩田 誠. ハンセン病ニューロパチーの臨床. Neuroinfection. 2010;15:16-21.
 
(5) 岩田 誠. ハンセン病ニューロパチーの臨床. Brain Nerve. 2011;63:157-64.
 

書評

最近チェックした商品履歴

Loading...